Future research will also need to address the effect of tumor mutational burden, PD-L1 status, mismatch repair efficiency, and tumor-infiltrating lymphocytes, given that all these factors have been associated with response to immune checkpoint inhibitor-based therapy [54,55,56,57]. This evidence concerns the gene CD274 and neoplasm.